Pancreatic Cancer Research

ResearcherJuntendo UniversityActive in the last 2 years

Toshio Fujisawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7367-0767; OpenAlex author ID A5044186686. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 12

  1. Evaluation of tumor detection capability for pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm in each MRI sequence. Co-author DOI 10.4103/sjg.sjg_91_26↗
  2. STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-refractory patients with unresectable pancr… Co-author DOI 10.1016/j.eclinm.2022.101731↗
  3. Pancreatic Adenocarcinoma With Strong Expression of Interleukin-13 Receptor α2 Shows a Poor Response to Gemcitabine-Based Chemotherapy. First author DOI 10.1097/mpa.0000000000002151↗
  4. Effect of Mirogabalin on Chemotherapy-induced Peripheral Neuropathy Caused by Gemcitabine Plus Nab-paclitaxel Therapy in Pancreatic Cancer Patients: A Pilot St… First author DOI 10.21203/rs.3.rs-948459/v2↗
  5. Duration of Reduced CA19-9 Levels Is a Better Prognostic Factor Than Its Rate of Reduction for Unresectable Locally Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers13164224↗
  6. IL-13Rα2 Is a Biomarker of Diagnosis and Therapeutic Response in Human Pancreatic Cancer. Co-author DOI 10.3390/diagnostics11071140↗
  7. Successful Management of Hemosuccus Pancreaticus due to Pancreatic Adenocarcinoma by Chemoradiotherapy. First author DOI 10.2169/internalmedicine.4372-19↗
  8. A Novel Role of Interleukin 13 Receptor alpha2 in Perineural Invasion and its Association with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12051294↗
  9. Analysis of interleukin-13 receptor alpha2 expression as a prognostic biomarker in surgically resected pancreatic cancer patients Co-author DOI 10.1186/2051-1426-3-s2-p88↗
  10. Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer. Co-author DOI 10.1371/journal.pone.0034437↗
  11. Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine. Co-author DOI 10.1002/ijc.25437↗
  12. Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer. Co-author DOI 10.1186/1479-5876-9-37↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroyuki Isayama · 8 shared papers, 2020–2026 · strength 1.06
  2. Yusuke Takasaki · 5 shared papers, 2021–2026 · strength 0.72
  3. Ko Tomishima · 5 shared papers, 2020–2026 · strength 0.71
  4. Raj K. Puri · 6 shared papers, 2011–2021 · strength 0.39
  5. Yasuhisa Jimbo · 1 shared paper, 2026 · strength 0.22
  6. Makoto Nishimura · 1 shared paper, 2023 · strength 0.16
  7. Yoko Matsuda · 1 shared paper, 2023 · strength 0.16
  8. Motohiko Kato · 1 shared paper, 2023 · strength 0.16
  9. Naohisa Yahagi · 1 shared paper, 2023 · strength 0.16
  10. Kazuki Takakura · 1 shared paper, 2023 · strength 0.16
  11. Tomio Arai · 1 shared paper, 2023 · strength 0.16
  12. Shomei Ryozawa · 1 shared paper, 2023 · strength 0.16
  13. Takao Itoi · 1 shared paper, 2023 · strength 0.16
  14. Hideyuki Saya · 1 shared paper, 2023 · strength 0.16
  15. Atsushi Nakajima · 2 shared papers, 2011–2020 · strength 0.12
  16. Ko Tomishima · 1 shared paper, 2021 · strength 0.11
  17. Yoshinori Ino · 1 shared paper, 2020 · strength 0.09
  18. Naoya Kato · 1 shared paper, 2020 · strength 0.09
  19. Shin Maeda · 1 shared paper, 2020 · strength 0.09
  20. Itaru Endo · 1 shared paper, 2020 · strength 0.09
  21. William Allen Gahl · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.